A Phase II Multicenter Study on the Treatment of Adult de Novo Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) With the Protein Tyrosine Kinase Inhibitor BMS-354825 [dasatinib]. EudraCT Number 2005-005107-42.
Latest Information Update: 23 Jan 2024
At a glance
- Drugs Dasatinib (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 12 Dec 2023 Results of a multilevel propensity score weighting analysis comparing rates of hematologic CR in four trials: LAL0904, LAL1205, LAL1509 and LAL2116 presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 07 Nov 2008 Status changed from recruiting to completed, based on information from ClinicalTrials.gov.
- 10 Dec 2007 First interim results in 23 patients presented at ASH 2007.